Saturday, October 31, 2026

Virgin Galactic Stock Went Up By Over 3% At Session Start On Monday

ViaNews Editorial Team

December 21, 2020

Virgin Galactic Stock Went Up By Over 3% At Session Start On Monday

Shares of Virgin Galactic jumped 3.4% to $24.65 at 10:02 EST on Monday, following yesterday's downward trend. The New York Stock Exchange is sliding 0.34% to $14,467.80, following yesterday's downward trend, This seems, up to now, a somewhat rough trend trading session today.

Virgin Galactic's last close was $25.50, 72.37% under its 52-week high of $42.49.

Virgin Galactic's Sales

Virgin Galactic's sales growth is 26.7% for the ongoing quarter and 715.1% for the next. The company's growth estimates for the ongoing quarter is a negative 170.5% and positive 23.3% for the next.

Virgin Galactic's Stock Yearly Top and Bottom Value

Virgin Galactic's stock is valued at $24.65 at 10:02 EST, way below its 52-week high of $42.49 and way higher than its 52-week low of $9.06.

Virgin Galactic's Moving Average

Virgin Galactic's worth is higher than its 50-day moving average of $24.46 and way above its 200-day moving average of $20.11.

Previous days news about Virgin Galactic

Virgin Galactic drops as holders file to sell 113 million shares. According to Bloomberg Quint on Fri Dec 18, "Virgin Galactic Holdings Inc. fell 4% in premarket trading Friday after shareholders filed to offer as much as 113 million of stock for sale.", "Last week, Virgin Galactic sank 17% after efforts to take tourists into space suffered a setback when a test flight was scrubbed shortly after takeoff because of a technical snag."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com